Table 2.
Outcomes of PrEP start visits by COVID-19 pandemic window and visit type
| PrEP start visit outcomes | Pre-COVID-19 PrEP Start Visits | Post-COVID-19 PrEP Start Visits | p valuea | Post-COVID19 PrEP Start Visits | ||
|---|---|---|---|---|---|---|
|
| ||||||
| In-clinic PrEP | TelePrEP | p valuea | ||||
| Laboratory completion (n, %) | N=341 | N=283 | N=140 | N=143 | ||
| Yes | 341 (100.0) | 278 (98.2) | 0.02 | 140 (100.0) | 138 (96.5) | 0.06 |
| No | 0 (0.0) | 5 (1.8) | 0 (0.0) | 5 (3.5) | ||
|
| ||||||
| Prescription filledb (n, %) | N=333 | N=271 | N=136 | N=135 | ||
| Yes | 308 (92.5) | 231 (85.2) | 0.005 | 115 (84.6) | 116 (85.9) | 0.86 |
| No | 25 (7.5) | 40 (14.8) | 21 (15.4) | 19 (14.1) | ||
|
| ||||||
| Follow-up visit at 3–4 monthsc (n, %) | N=43 | N=43 | N=21 | N=22 | ||
| Yes | 17 (39.5) | 21 (48.8) | 0.52 | 12 (57.1) | 9 (40.9) | 0.37 |
| No | 26 (60.5) | 22 (51.2) | 9 (42.9) | 13 (59.1) | ||
Abbreviations: PrEP = HIV pre-exposure prophylaxis; DSHC = Denver Sexual Health Clinic; telePrEP = PrEP services using telehealth.
a
A difference was deemed to be statistically significant if P<0.05. For clarity, statistically significant findings have been presented in boldface.
b
Prescription dispense status was not available for 20 clients (8 pre-COVID 19 and 12 post-COVID 19)
c
Follow-up visits at 3–4 months only included clients eligible for 3–4-month follow up visit through PHIP.